Generate report
Nordic Bioscience A/S
Herlev Hovedgade 205, 2730 Herlev, CVR 30799968
Company type
Limited Corporation
Established
2007
Size
Medium
Employees
167
Revenue
314
MDKK
Gross profit
263
MDKK
Operating Profit (EBIT)
140
MDKK
Profit for the year
113
MDKK
Equity
72
MDKK
Advertising protection
The company is advertising protected. This means that the information may not be used for marketing purposes. ad
More financial key figures and analyses?
In Bisbase Premium you get more financial key figures for both companies, groups and industries plus access to exclusive industries complied by experts. You can also create your own analyses! It only takes a minute or so - and it's free!
Rank Profit for the year
Rank in industry
4/992
"Top 10%"
Rank in Denmark
1,497/345,354
"Top 10%"
Top management top 3
| Morten Asser Karsdal 3 | Director |
Board top 3
| Claus Henrik Christiansen 13 | Boardmember |
| Thomas Nielsen 11 | Boardmember |
| Bente Juel Christiansen 9 | Boardmember |
Legal owners top 3
Rights certificate
Selskabet tegnes af to medlemmer af bestyrelsen i forening, af et medlem af bestyrelsen og en direktør i forening eller af den samlede bestyrelse.
Company information based on CVR
| Name | Nordic Bioscience A/S |
| Alternate names | Nordic Bioscience Assay Development A/S, Nordic Bioscience Compound Development A/S Show more |
| CVR | 30799968 |
| Address | Herlev Hovedgade 205, 2730 Herlev |
| Industry | Research and experimental development on biotechnology [721100] |
| Web | www.nordicbioscience.com |
| Established | 13-08-2007 (16 yr) |
| First financial statement period | 01-01-2007 to 31-12-2007 |
| Company type | Limited Corporation |
| Number of employees | 177 (man years:171) |
| Advertising protection | Yes |
| Auditor | Deloitte Statsautoriseret Revisionspartnerselskab since 04-09-2018 |
| Financial statement period | 01-01 to 31-12 |
| Company capital | 10,000,000 DKK |
| Articles of assoc. last | 10-09-2012 |
Member of industries
- Research and experimental development on biotechnologyNACE6 containing 544 comp.
- Research and experimental development on natural sciences and engineeringNACE3 containing 1,706 comp.
- Scientific research and developmentNACE2 containing 2,002 comp.
- Professional, scientific and technical activitiesNACE1 containing 86,660 comp.
Purpose
Selskabets formål er at drive virksomhed indenfor bioteknologi og anden dermed i forbindelse stående virksomhed, herunder at eje datterselskaber og kapitalandele i forbindelse hermed.
Financial Statement
| 2022 | 2021 | 2020 | |
|---|---|---|---|
| Currency/unit | 000' DKK | 000' DKK | 000' DKK |
| Revenue | 313,570 +16% | 271,014 - | - - |
| Gross Profit | 263,246 +10% | 239,141 -6% | 254,960 +18% |
| Profit for the year | 113,234 +8% | 104,796 +12% | 93,354 +26% |
| Equity | 71,667 -39% | 117,731 +4% | 113,378 -6% |
| Total Assets | 271,867 +2% | 265,898 +4% | 255,699 -4% |
Mangement review
Development in activities and financesThe Company’s income statement for the year ended 31.12.2022 shows a profit of DKK 113,233,569 while
the balance sheet shows equity of DKK 71,666,978 at 31.12.2022.
The Group have performed a IFRS conversion project (GAAP Analysis) to evaluate the impact of changing accounting policies to International Financial Reporting Standards (IFRS). The analysis showed differences in two areas: Certain development cost should be capitalized under IFRS and the historic applied revenue recognition principle was different compared to IFRS 15. Based on this, the Group have decided to change its accounting principles on these two areas. The change is further described in the Accounting Principles-section.
the balance sheet shows equity of DKK 71,666,978 at 31.12.2022.
The Group have performed a IFRS conversion project (GAAP Analysis) to evaluate the impact of changing accounting policies to International Financial Reporting Standards (IFRS). The analysis showed differences in two areas: Certain development cost should be capitalized under IFRS and the historic applied revenue recognition principle was different compared to IFRS 15. Based on this, the Group have decided to change its accounting principles on these two areas. The change is further described in the Accounting Principles-section.
28-06-2023